News

Examining an intraocular implant that can sharpen vision for patients as disease progresses.

Physician discusses preoperative assessments before procedure focusing on cornea.

According to the company, the funding supports the Phase 2 clinical study of ONL1204 ophthalmic solution to evaluate the safety and efficacy in patients diagnosed with macula-off rhegmatogenous retinal detachment.

According to the company, in a clinical trial of chloroprocaine hydrochloride ophthalmic gel in patients undergoing routine cataract surgery, patients treated with the gel did not require any supplemental treatment to complete the intended surgical procedure.

The researchers from Indiana University School of Medicine found neurons use mitochondria for a steady source of energy, and restoring mitochondrial homeostasis in the diseased neurons can protect the optic nerve cells from being damaged.

ICLs offer a strong surgical correction option for some patients.

The procedure can provide prolonged IOP lowering in primary open-angle glaucoma with an excellent safety profile.

Horizon Therapeutics presented data at the North American Neuro-Ophthalmology Society (NANOS) Annual Meeting, being held through March 16 in Orlando, Florida, summarizing real-world experience of people living with TED and DON who were treated with teprotumumab-trbw between January 2020 and September 2022.

While low-dose atropine eye drops are currently being used to slow myopia progression in several countries in Asia, researchers set out to determine if the medication could also the onset of myopia.

A look at what’s in the therapeutic delivery pipeline for these disorders.

Automated AI tool offers offline capability and hope for patients.

EMBL-EBI researchers use UK Biobank data to uncover new information about rare diseases of the eye.

For this study, researchers focused on photoreceptor cells (PRCs), which are light-detecting cells found in the retina.

As the company marks its 40-year anniversary, the new rebranding will become official on March 10, 2023, and will be followed by the introduction of new products.

According to the U.S. District Court, during the jury trial before U.S. District Judge Wilhelmina M. Wright, the United States proved that the defendants the Cameron-Ehlen Group, Inc., which does business as Precision Lens, and its owner Paul Ehlen paid kickbacks to ophthalmic surgeons to induce their use of Defendants’ products in cataract surgeries reimbursed by Medicare.

Celebrating 40-year anniversary with new brand/new products.

According to the company, post-hoc time-to-event analysis signals up to 59% risk reduction in rate of vision loss compared to sham treatment at 12 months. The analysis will be presented at the ARVO Annual Meeting from April 23-27 in New Orleans.

The Ergo-Series of the OMNI Surgical System maximizes ergonomics and surgical ease-of-use while continuing to enable surgeons to perform minimally invasive, implant-free glaucoma procedures.

A team of researchers compared 10-MHz and 15-MHz B-scan probes to evaluate the probes’ ability to detect and localize retinal detachments in eyes filled with silicone.

According to the company, the funding supports the Phase 2 clinical study of ONL1204 ophthalmic solution to evaluate the safety and efficacy in patients diagnosed with macula-off rhegmatogenous retinal detachment.

Avenova Eye Health Support oral supplement aims to comfort dry eyes and support overall eye health.

The 2023 Harrington Prize for Innovation in Medicine recognizes Jean Bennett, MD, PhD, and Albert M. Maguire, MD, for their work in retinal gene therapy for genetic diseases.

A look at what’s in the therapeutic delivery pipeline for these disorders.

The company’s Purely Soothing eye drop is used as an anti-inflammatory used to assist with symptoms of ocular irritation and/or swelling, including dry eye.

The month will help to bring awareness to eye safety in the workplace and keep eyes safe and protected on the job.

Alice Epitropoulos, MD, gives some insight into meibomian gland dysfunction (MGD), one of the most prevalent forms of dry eye.

The company’s therapeutic is a single therapy for multiple forms of age-related macular degeneration. NM3086 is a highly potent alternative pathway (AP) blocker that does not affect the classical pathway.

The voluntary recall is being issued out of an “abundance of caution” due to cracks that have developed in some of the units caps of the bottles.